ORIC.US Oric Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
7.86 USD
Close of Nov 15, 2026
7.23 14.68
Market cap
USD 815M
P/E
-
P/B
2.13x
ROE
-49.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ORIC.US undervalued?

Graham number

The Graham number of Oric Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oric Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Oric Pharmaceuticals Inc yet.

Oric Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oric Pharmaceuticals Inc

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth fact…

Full company profile